Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 497597, 6 pages
http://dx.doi.org/10.1155/2015/497597
Clinical Study

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA

Received 14 November 2014; Accepted 27 December 2014

Academic Editor: Francesco Onida

Copyright © 2015 Talha Badar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Cohen, C. A. de Moor, P. Eisenberg, E. E. Ming, and H. Hu, “Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings,” Supportive Care in Cancer, vol. 15, no. 5, pp. 497–503, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. M. Grunberg, “Obstacles to the implementation of antiemetic guidelines,” JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 5, pp. 601–605, 2009. View at Google Scholar · View at Scopus
  3. R. M. Navari, “Prevention of emesis from multiple-day and high-dose chemotherapy regimens,” JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 1, pp. 51–59, 2007. View at Google Scholar · View at Scopus
  4. R. McNulty, “Are all 5-HT3 receptor antagonists the same?” Journal of the National Comprehensive Cancer Network, vol. 5, no. 1, pp. 35–43, 2007. View at Google Scholar · View at Scopus
  5. R. J. Gralla, D. Osoba, M. G. Kris et al., “Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2971–2994, 1999. View at Google Scholar · View at Scopus
  6. S. M. Fox, L. H. Einhorn, E. Cox, N. Powell, and A. Abdy, “Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy,” Journal of Clinical Oncology, vol. 11, no. 12, pp. 2391–2395, 1993. View at Google Scholar · View at Scopus
  7. G. N. Mattiuzzi, J. E. Cortes, D. A. Blamble et al., “Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia,” Cancer, vol. 116, no. 24, pp. 5659–5666, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. F. Shanahan and G. C. O'Sullivan, “Neurokinin antagonism and chemotherapy-induced emesis,” The American Journal of Gastroenterology, vol. 94, no. 11, pp. 3368–3369, 1999. View at Google Scholar · View at Scopus
  9. L. Patel and C. Lindley, “Aprepitant—a novel NK1 -receptor antagonist,” Expert Opinion on Pharmacotherapy, vol. 4, no. 12, pp. 2279–2296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. D. G. Warr, P. J. Hesketh, R. J. Gralla et al., “Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2822–2830, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. J. Herrstedt, H. B. Muss, D. G. Warr et al., “Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy,” Cancer, vol. 104, no. 7, pp. 1548–1555, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. B. L. Rapoport, K. Jordan, J. A. Boice et al., “Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study,” Supportive Care in Cancer, vol. 18, no. 4, pp. 423–431, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. K. Jordan, F. Jahn, P. Jahn et al., “The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: Paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination,” Bone Marrow Transplantation, vol. 46, no. 6, pp. 784–789, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. W. Pielichowski, J. Barzal, K. Gawronski et al., “A triple-drug combination to prevent nausea and vomiting following beam chemotherapy before autologous hematopoietic stem cell transplantation,” Transplantation Proceedings, vol. 43, no. 8, pp. 3107–3110, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. Uchida, H. Ikesue, K. Kato et al., “Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy,” American Journal of Health-System Pharmacy, vol. 70, no. 4, pp. 343–349, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. H. F. Gao, Y. Liang, N. N. Zhou, D. S. Zhang, and H. Y. Wu, “Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy,” Internal Medicine Journal, vol. 43, no. 1, pp. 73–76, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus